Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.01
30.63
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Mayinglong Pharmaceutical Group Co Ltd
Common Shares Outstanding
Mayinglong Pharmaceutical Group Co Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
|
Common Shares Outstanding
¥431.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Common Shares Outstanding
¥5.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Common Shares Outstanding
¥603.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Common Shares Outstanding
¥6.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Common Shares Outstanding
¥1.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Common Shares Outstanding
¥401m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mayinglong Pharmaceutical Group Co Ltd
Glance View
In the corridors of China's pharmaceutical industry, Mayinglong Pharmaceutical Group Co Ltd stands out with its roots deeply embedded in history while its branches stretch ambitiously into the future. Founded in 1582 during the Ming Dynasty, this firm has garnered a reputation for its innovative approach to traditional Chinese medicine. The company's evolution from an apothecary serving local communities to a publicly traded enterprise mirrors the dynamic growth of China itself. As the world became increasingly captivated by holistic health solutions, Mayinglong capitalized on its heritage of time-tested remedies, turning ancient formulations into modern products. Their flagship product, Mayinglong Hemorrhoid Ointment, is a renowned success, both domestically and internationally, symbolizing the company's unique ability to blend ancient wisdom with contemporary health needs. Mayinglong's business model thrives on a well-balanced portfolio that includes not only traditional Chinese medicines but also a growing pipeline of innovative pharmaceuticals and healthcare products. Leveraging state-of-the-art technology in their R&D centers, they develop new drugs and therapies that align with both modern health trends and the regulatory demands of global markets. The group's revenue streams are diversified across multiple segments, including over-the-counter products, prescription medications, and personal care items. With a vast distribution network both in China and abroad, Mayinglong benefits from scale and brand recognition. Their strategy is a testament to the harmonious merger of tradition and modernity, driving profitability through a deep understanding of consumer needs paired with scientific innovation.
See Also
What is Mayinglong Pharmaceutical Group Co Ltd's Common Shares Outstanding?
Common Shares Outstanding
431.1m
CNY
Based on the financial report for Sep 30, 2024, Mayinglong Pharmaceutical Group Co Ltd's Common Shares Outstanding amounts to 431.1m CNY.
What is Mayinglong Pharmaceutical Group Co Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
0%
Over the last year, the Common Shares Outstanding growth was 0%.
You don't have any saved screeners yet
